What is the efficacy of varicella-zoster virus (VZV) vaccine (Varivax) in the preventions of herpes zoster (shingles)?

Updated: Feb 11, 2021
  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

Since 1995, live attenuated VZV vaccine (Varivax) has been available in the United States and has been up to 99% effective in protecting susceptible individuals from varicella infection. The higher-potency live attenuated VZV vaccine introduced in 2005 (Zostavax) has demonstrated a reduction in the incidence rate of 51.3% during 3 years of follow-up in one study. [122]

The routine use of the live attenuated varicella vaccine has led to a remarkable reduction in the incidence of primary varicella infection. Furthermore, vaccinated children have demonstrated lower rates of herpes zoster than those infected through natural exposure to VZV. [123, 124] However, the effect of childhood vaccination on the incidence of herpes zoster in adult populations remains to be fully elucidated.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!